Phio Pharmaceuticals Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.5M
- Price
- $0.99
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.95%
- Volume
- 7.4K
About
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Quick stats
Shares outstanding11.6M
Computed float11.2M
Float / shares96.3%
Cash runway (months)8.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001533040
Websitehttps://www.phiopharma.com
AI Summary
AI-generated1/29
minorneutralother
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Phio Pharmaceuticals announced that CEO Robert Bitterman will present its INTASYL siRNA platform and strategic direction at The Global Markets Virtual Forum on October 8, 2026, at 12:40 PM EDT.
Bitterman will also be available for one-on-one investor meetings across October 8-12, and an archived webcast will be available after the live event.
The release contains no new clinical or financial data; the lead program PH-762 remains in Phase 1b for skin cancers, with FDA interactions and next-phase activities expected to progress through Q1 2027.